Cellectis
CLLS
#9601
Rank
HK$0.93 B
Marketcap
HK$9.26
Share price
-6.35%
Change (1 day)
-73.08%
Change (1 year)

Earnings for Cellectis (CLLS)

Earnings in 2026 (TTM): -HK$0.52 Billion

According to Cellectis's latest financial reports the company's current earnings are HK$56.57 Million. In 2025 the company made an earning of -HK$0.54 Billion a decrease over its 2024 earnings that were of -HK$0.29 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Cellectis from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -HK$0.52 Billion-3.83%
2025 -HK$0.54 Billion85.03%
2024 -HK$0.29 Billion-73.42%
2023 -HK$1.09 Billion60.8%
2022 -HK$0.68 Billion-31.26%
2021 -HK$0.99 Billion27.21%
2020 -HK$0.78 Billion-14.62%
2019 -HK$0.91 Billion30.34%
2018 -HK$0.7 Billion-15.03%
2017 -HK$0.82 Billion62.18%
2016 -HK$0.51 Billion185.48%
2015 -HK$0.18 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Regeneron Pharmaceuticals
REGN
HK$40.53 B-7,967.20%๐Ÿ‡บ๐Ÿ‡ธ USA
uniQure
QURE
-HK$1.93 Billion 273.36%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
-HK$1.76 Billion 240.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
-HK$0.63 Billion 20.90%๐Ÿ‡บ๐Ÿ‡ธ USA